EpiDisease, a biotechnology company located in the Science Park of the University of Valencia, announces, in collaboration with the company Matisse Pharmaceuticals B.V. the launch of the eHISTOCURE project, recently approved under the EUROSTARS programme with a total funding of € 960,000. In Spain, the project is partially supported by the Centre for Technological Development and Innovation (CDTI)
EpiDisease S.L., a biotechnology company specialized in epigenetics and precision diagnostics located in the business area of the Science Park of the University of Valencia (PCUV), in collaboration with the company Matisse Pharmaceuticals B.V., a clinical-phase biopharmaceutical company developing therapeutic molecules for sepsis and septic shock, announces the launch of the eHISTOCURE project, which has recently been awarded by the EUROSTARS programme for a total of €960,000, partly financed by the Spanish Centre for Technological Development and Innovation (CDTI).
The main objective of the project developed by EpiDisease is to validate HistSHOCK CDx, an in vitro diagnostic test based on mass spectrometry (LC-MS/MS) for the quantification of circulating histones in the plasma of patients with sepsis and septic shock. This innovative test will allow early identification of patients who may benefit from treatment with M6229, an experimental drug with extracellular histone-neutralizing and anti-inflammatory properties currently in clinical development (Phase IIa) for the treatment of severe sepsis.
The joint implementation of HistSHOCK CDx and M6229 represents a precision medicine therapeutic approach to reduce high mortality associated with septic shock, which remains one of the leading causes of death in intensive care units (ICUs) at global level.
The joint implementation of HistSHOCK CDx and M6229 represents a precision medicine therapeutic approach to reduce high mortality associated with septic shock, which remains one of the leading causes of death in intensive care units (ICUs) At the global level
HistSHOCK CDx is an in vitro diagnostic test based on mass spectrometry (LC-MS) to detect circulating histones in patients with sepsis. Identifies which patients may benefit from M6229 treatment, improving stratification and clinical decision-making in intensive care units.
Meanwhile, M6229 is a research drug aimed at the treatment of sepsis and septic shock. Its mechanism of action is based on the inhibition of cytotoxic effects of extracellular histones, molecules which, when released into the bloodstream, trigger an exacerbated systemic inflammatory response. M6229 is designed to block mechanisms that induce the inflammatory cascade, improve patients' hemodynamic stability and increase their chances of survival.
The project currently underway has a clear roadmap towards the commercialization of a diagnostic tool that could transform the current form of sepsis management in critical hospital environments.
EpiDisease Laboratory, which announces the launch of the eHISTOCURE project. Photo: EpiDisease
About EpiDisease
EpiDisease is a biotechnology company based in PCUV and focused on the development of diagnostic solutions based on epigenetic biomarkers. Its mission is to advance personalized medicine through high precision diagnostic tools.
Epidisease’s business objective is the research, technological development and marketing of epigenetic-based products and services in the field of molecular diagnostics focused on medical and health activities. The services provided by Epidisease include: DNA methylation analysis; analysis of post-translational modifications in histones; study of microRNAs expression; identification of circulating microRNAs in biological fluids; the characterisation of new epigenetic biomarkers and the in vitro study of the epigenetic activity of bioactive molecules.
In addition, the company has recently been selected as part of the DiBaN consortium, a €4 million European project to develop innovative foods that improve metabolic health and prevent chronic diseases such as type 2 diabetes.
Don’t miss our Europark video with James Webb, EpiDisease commercial director
Source: EpiDisease